Professor Wei Chen’s publication in Elsevier Cancer Letters an international journal
October 16, 2024
Congratulations to Professor Wei Chen and his lab University of Oklahoma for their publication titled “Localized ablative immunotherapy enhances antitumor…
SITC Immuno-Oncology Drug Development Summit September 30 – October 1, 2024
October 3, 2024
Siu Kit “Samuel” Lam, PhD, Senior Vice President of Science & Research at Immunophotonics, Inc. attended the SITC Immuno-Oncology Drug…
Professor Wei Chen’s Publication in Advanced Science News – Advanced Functional Materials
October 1, 2024
Immunophotonics wants to congratulate Professor Wei Chen and his lab University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K.…
Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3
September 13, 2024
Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 --seamlessly integrated into the clinical workflow--…
CIRSE 2024 September 14 to 18 and ESMO 2024 September 16
September 12, 2024
Immunophotonics co-founders Lu Alleruzzo (CEO), Tomas Hode, PhD (CIO and President), and David Anderson, PhD (CSO) are excited to be…
Immunophotonics Winner of the Startup World Cup St Louis Regional Finals
September 10, 2024
Immunophotonics won the Startup World Cup St. Louis Regional finals. A big thank you to Emily Hemingway and her team…
Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of Louisville
August 15, 2024
We are thrilled to announce that Dr. Robert Martin has successfully enrolled and treated the first patient in our groundbreaking…
Professor Wei R. Chen Organizes Immunophotonics Session at Gordan Research Conference
August 6, 2024
Immunophotonics is excited to share that Wei Chen, co-inventor of IP-001, Stephenson Chair, professor and interim director of the Stephenson…
Immunophotonics featured in Pharma Tech Outlook magazine
July 30, 2024
Immunophotonics is excited to be featured in Pharma Tech Outlook magazine in the Immunotherapy edition. Immunophotonics innovative approach could transform…
Authorization to Proceed Received on Immunophotonics’ INJECTABL-2 Clinical Trial
July 16, 2024
Immunophotonics is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific…